医学
彭布罗利珠单抗
重症肌无力
肌炎
无容量
心肌炎
皮疹
不利影响
内科学
银耳霉素
易普利姆玛
癌症
胃肠病学
外科
免疫疗法
作者
Biji Soman,Maria Cecilia Dias,Syed Azhar J Rizvi,Attila Kardos
出处
期刊:Case Reports
[BMJ]
日期:2022-12-01
卷期号:15 (12): e251966-e251966
被引量:10
标识
DOI:10.1136/bcr-2022-251966
摘要
Pembrolizumab, a humanised monoclonal antibody and immune checkpoint inhibitor (ICI) that blocks programmed death receptor 1 and its ligands, is an effective immunotherapy for malignancies such as melanoma , lung, head and neck, cancers, and Hodgkin’s lymphoma. It has an overall response rate between 73% and 83%, with complete response rate of 27%–30%. It is well tolerated with minor side effects in 70% of cases characterised by fatigue, rash, pruritus and diarrhoea. In rare cases, more serious and life-threatening complications can occur at a rate of 0.3%–1.3%. We report a case of a woman in her 70s with non-small-cell lung cancer treated with ICI. She presented to the emergency department with left-sided ptosis and muscle weakness 3 weeks of her first dose of pembrolizumab infusion as a treatment plan of her cancer. She was diagnosed with myasthenia gravis, myocarditis and myositis as ICI-induced immune-related adverse effects resistant to medical intervention. We wish to raise awareness of the triad of life-threatening complication of ICI therapy that accounts for 30%–50% of fatal complications.
科研通智能强力驱动
Strongly Powered by AbleSci AI